UCB's current portfolio faces key patent losses over the next 10 years, but successful pipeline development could help the firm fill some of the gaps. Among UCB's central nervous system therapies ...

UCB’s robust pipeline, built with partners is important as it allows us to maximize our collective resources and expertise which in turn will see us enter a new era of productivity for the ...

UCB's portfolio faces key patent losses over the next 10 years, but successful pipeline development could help the firm offset the negative impact of generic competition. Among UCB's central ...

The first phase 3 data with UCB’s key pipeline drug bimekizumab show that it hit all its efficacy targets in psoriasis – and performed better than Johnson & Johnson’s blockbuster rival Stelara.

Alpha-Synuclein Inhibitors Pipeline: Late-Stage Products (Pre-registration ... and key Parkinson's disease companies, including UCB Biopharma SRL, Novartis, Annovis Bio, Supernus Pharmaceuticals ...